Adverse events and efficacy of TNF-  blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

Aringer, Martin; Houssiau, Frédéric; Gordon, Caroline; Graninger, Winfried; Voll, Reinhard; Rath, Eva; Steiner, Guenter; Smolen, Josef S

doi:10.1093/rheumatology/kep270

Cited by 178 publications

(113 citation statements)

References 19 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Finally, in patients with lupus nephritis, 10 weeks of infliximab treatment reduced proteinuria but increased anti-DNA antibodies. Longer treatment was associated with adverse effects (68). In patients with RA treated with anti-TNF-a mAbs, lupus syndromes developed, anti-DNAs were induced (69), and some patients developed GN (70).…”

Section: Autoimmune Crescentic Glomerulonephritis Lupus Nephritismentioning

confidence: 99%

Cytokines

Holdsworth

Gan

2015

Clinical Journal of the American Society of Nephrology

118

View full text Add to dashboard Cite

Cytokines play an important role in host defense against microorganisms. They orchestrate innate immunity by inducing protective local inflammation and systemic acute phase responses. Cytokines are important in initiating, amplifying, directing, mediating, and regulating adaptive immunity. Unfortunately, they may also direct tissue damage if excessive responses occur or if they are involved in directing and mediating autoimmunity. Under these circumstances, cytokines are potential therapeutic targets. Over the last 20 years, we have seen the successful development and clinical implementation of biologic strategies that target key cytokines in specific inflammatory diseases with efficacy, specificity, and toxicity profiles challenging conventional drug therapies. These therapies are finding new applications and many new agents show promise. Unfortunately, these new cytokine-based therapies have had little effect on renal disease. This review provides evidence that common renal diseases, including those causing AKI and the autoimmune proliferative and crescentic forms of GN, have cytokine mediation profiles that suggest they would be susceptible to cytokine-targeting therapeutic strategies.

show abstract

Section: Autoimmune Crescentic Glomerulonephritis Lupus Nephritismentioning

confidence: 99%

Cytokines

Holdsworth

Gan

2015

Clinical Journal of the American Society of Nephrology

118

View full text Add to dashboard Cite

show abstract

“…There is little evidence for the severity of LP in immunosuppressed patients, although one study following up patients with systemic lupus erythematosus taking infliximab reported a death secondary to LP. 25 However, only a small number in our series were im-munosuppressed or had chronic kidney disease.…”

Section: Diagnosis and Treatmentmentioning

confidence: 70%

Legionella pneumonia cases over a five-year period: a descriptive, retrospective study of outcomes in a UK district hospital

Wingfield

Rowell²,

Peel

et al. 2013

Clinical Medicine

View full text Add to dashboard Cite

-As the recent outbreaks in Edinburgh andCamarthen, UK, have shown, Legionella pneumonia (LP) remains a significant public health problem, which is not only confined to those who have travelled abroad. In both outbreaks and sporadic cases, diagnosis can go unrecognised. We reviewed the demographics, comorbidities, diagnosis, treatment and clinical outcome of LP cases over five years in a district general hospital in northwest England. Over half of LP cases were UK acquired and 'classic' clinical features were common. Clinical criteria for diagnosing LP were confirmed, but few sputum samples were sent to reference laboratories, limiting further essential epidemiological mapping of UK cases. Following current UK community-acquired pneumonia guidance would have missed nearly one quarter of LP cases in our series, potentially leading to further morbidity and mortality.

show abstract

“…Pro-inflammatory cytokines IL-1β and TNF-α were reduced following treatment with FK228 [89]. TNF-α is known to play an important role in the pathogenesis of a number of autoimmune diseases including SLE, RA, and Crohn's disease and anti-TNF-α therapies have proven to be an effective clinical treatment for people with these diseases [38, [90][91][92][93]. The molecular mechanism through which FK288 reduces inflammation has yet to be determined.…”

Section: Selective Class I Inhibitorsmentioning

confidence: 99%

Isoform-Selective HDAC Inhibition in Autoimmune DiseaseNicole L Regna1* and Christopher M Reilly2

Regna

Reilly²

2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Histone deacetylases are a class of enzymes that play an important role in protein modification and cellular function. Ongoing research suggests that HDAC inhibitors may be efficacious in the treatment of a wide range of diseases from cancer to autoimmune disease. HDACi therapy has shown promising results both in vitro and in vivo for the treatment of autoimmune disease. To date, 18 isoforms of HDACs have been identified, which exist in four different classes: class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9, and 10) class III (sirtuins1-7), and class IV (HDAC11). The mechanism of action through which HDACs function remains to be fully elucidated. However, the use of isoform-selective HDAC inhibitors has been helpful in determining the physiological role of individual HDACs as well as in decreasing the toxicity of HDACi therapy. This review will focus on isoform-selective HDACs and how they may be effective for the treatment of autoimmune disease.

show abstract

Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

Cited by 178 publications

References 19 publications

Cytokines

Cytokines

Legionella pneumonia cases over a five-year period: a descriptive, retrospective study of outcomes in a UK district hospital

Isoform-Selective HDAC Inhibition in Autoimmune DiseaseNicole L Regna1* and Christopher M Reilly2

Contact Info

Product

Resources

About